Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Recruiting

Phase 3

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Sponsor:

ECOG-ACRIN Cancer Research Group

Code:

NCT02201992

Conditions

ALK Gene Rearrangement

ALK Gene Translocation

ALK Positive

Stage IB Non-Small Cell Lung Carcinoma AJCC v7

Stage II Non-Small Cell Lung Cancer AJCC v7

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Clinical Observation

Crizotinib

Laboratory Biomarker Analysis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group on 2024-07-03.